<DOC>
	<DOCNO>NCT02473393</DOCNO>
	<brief_summary>To assess safety , efficacy pharmacokinetics multiple dosesin patient Bacterial Enteritis cause Clostridium difficile infection ( CDI ) Enteric infection .</brief_summary>
	<brief_title>A Clinical Trial Assess Three Different Doses OPS-2071 Patients With Bacterial Enteritis</brief_title>
	<detailed_description />
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>The patient provide write , informed consent clinical trial initiate The patient distinctive symptom finding bacterial enteritis The patient bacterial enteritis one follow causative pathogen either proven presume : C. difficile , Salmonella , Campylobacter , pathogenic E. coli , bacteria estimate cause bacterial enteritis The patient his/her partner willing take contraceptive measure initiation investigational medicinal product ( IMPs ) 4 week administration IMPs The patient severe progressive underlying disease complication , make difficult ensure safety study proper efficacy assessment The patient current diagnosis history convulsive disorder , convulsion epilepsy The patient severe hepatic dysfunction The patient severe cardiac dysfunction The patient cardiac arrhythmia congenital sporadic long QTc syndrome . Or patient treat drug report prolong QTc interval The patient moderate severe renal dysfunction Women confirm suspected pregnancy breastfeed woman Patients judge ineligible investigator reason</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>